Inhibikase Therapeutics Inc (IKT) News

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 8-K - Current report

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT...

Form PRE 14A - Other preliminary proxy statements